StockStory
Jazz Pharmaceuticals Earnings: What To Look For From JAZZ
📈
AI Sentiment
Highly Positive
8/10
- Home
- JAZZ
as of 02-26-2026 3:50pm EST
$189.20
$7.63
-3.88%
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
| Founded: | 2003 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN |
| Market Cap: | 10.4B | IPO Year: | 2007 |
| Target Price: | $211.25 | AVG Volume (30 days): | 920.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.84 | EPS Growth: | -167.51 |
| 52 Week Low/High: | $95.49 - $197.47 | Next Earning Date: | 05-15-2026 |
| Revenue: | $1,618,693,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 7.6% | Revenue Growth (next year): | 8.34% |
| P/E Ratio: | -33.70 | Index: | N/A |
| Free Cash Flow: | 1.3B | FCF Growth: | -4.48% |
AI-Powered JAZZ Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 75.00%
75.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Jazz Pharmaceuticals plc (Ireland) (JAZZ)
Henderson Mary Elizabeth
Sell
SVP, Technical Operations
JAZZ Dec 9, 2025
Avg Cost/Share
$169.51
Shares
2,238
Total Value
$379,365.62
Owned After
19,508
SEC Form 4
Carr Patricia
Sell
SVP, Chief Accounting Officer
JAZZ Dec 5, 2025
Avg Cost/Share
$171.16
Shares
4,660
Total Value
$797,783.00
Owned After
7,012
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Henderson Mary Elizabeth | JAZZ | SVP, Technical Operations | Dec 9, 2025 | Sell | $169.51 | 2,238 | $379,365.62 | 19,508 | |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Dec 5, 2025 | Sell | $171.16 | 4,660 | $797,783.00 | 7,012 |
Latest Jazz Pharmaceuticals plc (Ireland) News
JAZZ Breaking Stock News: Dive into JAZZ Ticker-Specific Updates for Smart Investing
Compare JAZZ vs Leading Stocks
See how JAZZ stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "JAZZ Jazz Pharmaceuticals plc (Ireland) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.